ERBB2 and neoplasm: In our ER+/PgR-/HER2-/ Ki-67 <20% group, patients with luminal B tumours showed no significant difference in terms of all the prognostic factors when comparing to patients with ER+/PgR+/HER2-/ Ki-67 <20% tumours.